<DOC>
	<DOCNO>NCT01208480</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Drugs use chemotherapy , docetaxel carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving bevacizumab together docetaxel carboplatin may kill tumor cell . PURPOSE : This phase II trial study well give bevacizumab together docetaxel carboplatin work treat woman operable Stage II stage III breast cancer .</brief_summary>
	<brief_title>Bevacizumab , Docetaxel , Carboplatin Treating Women With Stage II Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To determine rate pathological complete response woman operable triple-negative breast cancer treat neoadjuvant bevacizumab , docetaxel , carboplatin . OUTLINE : This multicenter study . Patients receive bevacizumab IV , docetaxel IV , carboplatin IV day 1 . Treatment repeat every 3 week 5 course absence disease progression unacceptable toxicity . Patients receive docetaxel IV carboplatin IV course 6 . Patients undergo surgery week 19-21 plan .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive breast cancer Stage II III disease No evidence metastasis ( M0 ) No inflammatory breast cancer ( T4d ) Must primary tumor Operable disease Triplenegative disease , meet follow criterion : Estrogen receptor , progesterone receptor , HER2negative immunohistochemistry ( IHC ) 0 1+ OR fluorescence situ hybridization negative ( case IHC 2+ ) PATIENT CHARACTERISTICS : ECOG performance status 01 Pre postmenopausal Not pregnant Absolute granulocyte count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥10 g/dL Serum creatinine ≤ 1.5 mg/dL Total bilirubin ≤ 1.5 mg/dL AST/ALT ≤ 2 time normal Alkaline phosphatase ≤ 2 time normal Normal nonspecific EKG LVEF ≥ 50 % MUGA echocardiogram Normal mental function understand sign write informed consent No history uncompensated congestive heart failure No history cancer except carcinoma situ uterine cervix nonmelanoma skin cancer No history evidence inherit bleed diathesis coagulopathy risk bleed No uncontrolled hypertension ( systolic BP &gt; 150 mm Hg and/or diastolic BP &gt; 100 mm Hg ) No history evidence clinically significant cardiovascular disease , include follow : Cerebrovascular accident ( CVA ) stroke within past 6 month Myocardial infarction ( MI ) within past 6 month Unstable angina NYHA class IIIV congestive heart failure Serious cardiac arrhythmia require medication No serious nonhealing wound , peptic ulcer , bone fracture No history abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 6 month No know hypersensitivity study drug PRIOR CONCURRENT THERAPY : No prior hormone therapy , chemotherapy , radiotherapy breast cancer No prior breast surgery biopsy confirm diagnosis No concurrent chronic daily corticosteroid ( 10 mg/day methylprednisolone equivalent )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>triple-negative breast cancer</keyword>
</DOC>